林丽珠运用健脾疏肝法干预原发性肝癌TACE术后患者的临床经验

中图分类号：R273.57 文献标志码：ADOI：10.13359/j.cnki. gzxbtcm.2025.11.031

文章编号：1007-3213（2025）11-2845-07

Abstract：Asan adjuvant therapy，transarterial chemoembolization（TACE）can prolong the disease-free survival and overallsurvival of patients with primary liver cancer （PCL）.However，postoperative adverse reactions andrecurrence stillpossibly persist.Based onyears of clinical practice，Profesor Lin Lizhu proposes that patients with PCL undergoing TACE exhibit pathological mechanisms characterized bydeficiency，stagnation，toxicity， and stasis.In clinical practice，these patientscan be treated with Chinese herbal medicine based on the therapeutic principle of strengthening spleen and soothing liver.The treatment strategy involves：invigorating spleen and stomach to restore healthy qi ，soothing liver and nourishing blood to support liver function，and detoxifying and dispersing stasis to prevent recurrence.Derived from the classc formula Sini San，Professor Lin has developed Sini Kang'ai Formula，which mainly consists of Eupolyphaga Steleophaga，Bupleuri Radix， Paeoniae Radix Alba，Aurantii Fructus Immaturus， Glycyrrhizae Radix et Rhizoma， Codonopsis Radix， Persicae Semen，Cremastrae Pseudobulbus Pleiones Pseudobulbus，etc.In clinical application，Sini Kang'äi Formula should be flexibly modified depending on the characteristic symptom patterns of patients during the perioperative period of TACE，thus to alleviate postoperative adverse reactions，prevent tumor recurence， prolong disease-free survival and overall survival，and improve patients’quality of life.

Keywords：primary liver cancer（PCL）；transarterial chemoembolization（TACE）；strengthening spleen and soothing liver；invigorating spleen and stomach；sothing liver and nourishing blood；detoxifying and dispersing stasis； Sini Kang 'ai Formula； tumor recurrence； postoperative adverse reactions； Lin Lizhu

原发性肝癌（primarylivercancer，PCL）是我国最常见的恶性肿瘤之一。（剩余11227字）